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Purpose. Perioperative cerebral microembolization demonstrated on diffusion-weighted MRI (DWI) can occur following carotid
endarterectomy (CEA) and carotid artery stenting (CAS). We sought to explore potential risk factors for this in the large patient
cohort. Methods. We reviewed a 6-year consecutive patient cohort that received either CEA or CAS, and perioperative DWI
evaluations. Results. 303 patients were reviewed, and 56 (19.4%) patients were found to have perioperative microemboli. The
incidence was higher among patients who received CAS (P < 0.001). Hypertension (P = 0.03), smoking (P = 0.001), and a history
of transient ischemic attacks (P = 0.04) were risk factors for microembolization. The risk was higher among CEA patients with
obesity (P = 0.05), and among CAS patients with coronary artery disease (P = 0.03). Conclusion. Specific patient populations are
likely more prone to develop perioperative cerebral microemboli following carotid intervention. Continued risk stratification may
help decrease future perioperative cerebral microembolization rates.

1. Introduction
Perioperative cerebral microembolic events are known to
occur with either carotid endarterectomy (CEA) or carotid
artery stenting (CAS) [1–3]. Diffusion weighted MRI (DWI)
combined with apparent diffusion coefficient (ADC) mapping has emerged as an ideal tool to accurately diagnose
these events [2, 4, 5]. Despite the absence of associated
neurological symptoms with cerebral microemboli, we and
others have demonstrated their potential effects on shortterm memory loss and cognitive decline [6–8]. With our
improved ability to diagnose and evaluate consequences of
these events, patient-associated factors that can potentially
influence the perioperative incidence of these events are yet
to be fully elucidated [8–10].

In recent years, specific device modifications, as well
as improved procedural and technical factors have led to
noticeable declines in the rates of perioperative cerebral
microembolization [1, 11]. However, despite these modifications, perioperative microembolization still occurs, suggesting that, in addition to procedural factors, patient-centered
factors may also influence the incidence of these events [12].
We previously demonstrated that patient factors, such as
age and specific comorbidities, can potentially influence a
patient’s risk of these perioperative events [13]. As a followup to these findings, we offer a more comprehensive review of
a large single-center and consecutive cohort of patients here,
to determine patient-centered risk factors for perioperative
cerebral microembolization following either CEA or CAS.
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2. Methods
2.1. Study Patients. All patients who underwent either CEA
or CAS, from July 2004 to December 2010, at our institution
were prospectively enrolled in an investigational study protocol, and retrospectively reviewed. The protocol hypothesis,
objectives, and methods were approved by our local Institutional Review Board (IRB) and Research and Development
Committee. Patients excluded from the study included those
who were not eligible or unable to receive perioperative head
and neck MRIs. Written consent was obtained from each
study participant.
For diagnostic purposes, all patients scheduled for either
CAS or CEA first underwent a preoperative carotid duplex
scan to determine the extent of hemodynamically significant
carotid artery stenosis. Generally, our criterion for carotid
artery intervention was a vascular duplex demonstrating
a hemodynamically significant stenosis of ≥60% in symptomatic patients, or ≥80% stenosis in asymptomatic patients.
The majority of patients also routinely underwent cardiac
evaluations including a persantine-thallium nuclear stress
test. A cardiology referral was routinely obtained for patients
who were found to have preoperative abnormal cardiac
evaluations.
2.2. Data Collection. Retrospective chart review was performed to gather patient characteristics including age group
(<60, 61–70, 71–80, and >80 years old) and gender. Comorbidities such as hypertension, hyperlipidemia, diabetes mellitus, chronic obstructive pulmonary disease, coronary artery
disease (history of prior myocardial infarction, defects on
cardiac perfusion scan, or as noted on prior coronary
angiogram), peripheral vascular disease (history of claudication/rest pain, reduced ankle-brachial indexes, or as noted on
prior extremity angiogram), arrhythmia, obesity (as defined
by a body mass index of ≥30), and smoking were reviewed. A
past medical history notable for transient ischemic attack and
stroke was also noted. Carotid anatomy and plaque characteristics were examined, and plaque calcification was defined as
plaque that appeared >50% calcified on diagnostic imaging.
The incidence of periprocedural neurologic symptoms, such
as gross motor and/or sensory defects, was identified based
on the review of patient medical records, which included the
inpatient progress notes, discharge summaries, and subsequent outpatient clinic evaluations.
2.3. MRI Imaging and Interpretation. All patients included in
the study underwent a preoperative MRI one to three weeks
prior to the scheduled carotid revascularization procedure.
A postoperative MRI was also performed within 48 hours
of the procedure. The majority of postoperative MRIs were
obtained the morning following the procedure (24 to 48
hours postoperatively).
Imaging was performed with a 1.5-T apparatus (Signa
Excite HD 12.0, GE Medical Systems, Piscataway, NJ, USA)
equipped with a head coil. The brain was scanned utilizing multiple pulse sequences in the axial, sagittal, and
coronal planes both before and after contrast administration. Both pre- and postoperative MRIs routinely included
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axial spin-echo (SE) T1-weighted, fast-spin echo (FSE) T2weighted, fluid-attenuated inversion-recovery (FLAIR), diffusion weighted (DW), and postcontrast SE T1-weighted
sequences. The DWI images were acquired with an isotropic
echo-plantar sequence (6500/97/1/TR/TE/NEX, field of view
280 mm, matrix 128×128, with 𝑏 values of 0 and 1000 s/mm2 ).
An ADC map was also automatically generated for each
MRI. As previously described, all MRI images were evaluated
by a board certified neuroradiologist. The presence of a
new hyperintensity on postoperative DWI sequences with
corresponding hypointensity on the ADC mapping was
interpreted as a new microembolic ischemic lesion [13, 14].
The number of new microembolic lesions on postoperative
MRI studies was evaluated.
2.4. CEA. All CEAs were performed by board certified or
board eligible vascular surgeons under general anesthesia.
In addition to daily Aspirin 81 mg, all patients were administered Heparin (100 U/kg) routinely before carotid crossclamping. Intraoperative cerebral oximetery monitoring by
the anesthesiology team was used in all cases. Routine intraoperative common carotid to internal carotid artery shunting
was performed. Carotid patch types were up to the discretion
of the individual surgeon. Postoperatively, all patients were
admitted to the surgical intensive unit for observation and
MRI evaluations were typically performed on postoperative
day one prior to hospital discharge if the patients were
hemodynamically stable. All patients were maintained on a
daily Aspirin 81 mg.
2.5. CAS. Two vascular surgeons in the institutional practice
group were designated to perform all of the CAS procedures.
The decision to pursue CAS was made collaboratively among
the patients, vascular surgeons, cardiologists, and referring
physicians. As previously described, we determined patient
eligibility based on medical and anatomical criteria. CAS
was considered a viable alternative in patients with recent
myocardial infarction within the previous three months,
reversibility on cardiac perfusion study, steroid-dependent
chronic obstructive pulmonary disease, or a forced expiratory
volume in 1 second (FEV1) <30% of predicted. Patients with
a high carotid bifurcation (above the C2 vertebral level),
tracheostomy, history of ipsilateral neck irradiation, prior
neck dissection, or prior carotid endarterectomy were also
considered for CAS.
All CAS procedures were performed in an endovascular
suite with arterial line access and anesthesia monitoring.
The technical details of CAS were performed as previously
described from a transfemoral approach with the routine
use of distal embolic protection devices (EPDs; Accunet,
Guidant, Inc., Sunnyvale, CA; Emboshield, Abbott Inc., Santa
Clara, CA) and self-expanding stents (Acculink, Guidant,
Inc.; XACT, Abbott Inc.) [1]. Following CAS procedures,
patients were similarly transferred to the surgical intensive
care unit for close hemodynamic monitoring. All patients
were started on daily Clopidogrel. Pending hemodynamic
stability, the majority of patients received an MRI on postoperative day one. All patients were discharged on life-long
Aspirin 81 mg and a 6-week course of Clopidogrel.
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Table 1: Preoperative demographics of study patients.

Demographics
Age
<60
61–70
71–80
>80
Male
Smoking
Diabetes
Hypertension
Hyperlipidemia
Obesity (BMI > 30)
CAD
COPD
PVD
Atrial fibrillation
Prior CEA
Prior TIA
Prior Stroke
Contralateral carotid Occlusion
Plaque calcification

Overall (𝑛 = 288)

CEA (𝑛 = 171)

CAS (𝑛 = 117)

16.7%
39.2%
29.2%
14.9%
98.3%
31.9%
69.4%
68.1%
89.6%
68.1%
48.6%
39.9%
25.7%
29.9%
26.0%
29.2%
21.8%
7.6%
15.3%

18.2%
39.7%
27.4%
14.6%
99.4%
15.1%
78.5%
51.7%
94.8%
93.0%
31.4%
47.7%
15.6%
39.0%
20.9%
22.1%
19.2%
5.2%
7.0%

14.5%
38.4%
31.7%
15.4%
96.6%
56.9%
56.0%
92.2%
81.9%
31.0%
74.1%
28.4%
40.5%
16.4%
33.6%
39.7%
25.9%
11.2%
27.6%

𝑃 Value
0.98

0.16
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
<0.001
0.02
<0.01
0.25
0.07
<0.001

BMI: body mass index; CAD: coronary artery disease; COPD: chronic obstructive pulmonary disease; PVD: peripheral vascular disease.

3. Statistics
Patients were stratified based on the incidence of DWIevident microemboli. Patient demographics, comorbidities,
and anatomical characteristics were compared between
patients who received either CEA or CAS. Fisher’s exact
test was used for univariate analysis of categorical variables,
and Student’s 𝑡-test was used for univariate analysis of
continuous variables. Rates of microemboli following carotid
intervention were analyzed across different age groups using
a two-way ANOVA analysis with Bonferroni correction.
Multivariate logistic regression analysis was performed to
identify variables that significantly predicted patients who
developed periprocedural microemboli. Statistical significance was predetermined at an alpha of .05 (𝑃 = .05, twotailed). All statistical analysis was performed using SPSS
Statistics 17.0 (SPSS Inc., Chicago, IL).

4. Results
From July 2004 to December 2010, 303 patients underwent
carotid intervention at our institution. Of these patients, 288
patients met study inclusion criteria and received both preand postoperative head and neck MRIs with DWI sequences.
As illustrated in Figure 1, 171 patients received CEA and 117
received CAS.
Several notable differences in demographics, medical
comorbidities, neurological history, and carotid anatomical characteristics were observed between patients who
underwent either CEA or CAS. Major comorbidities among
patients who received CEA included diabetes (78.5%) and
hyperlipidemia (94.8%; Table 1). Compared to patients who

June 2004 to December 2010

303 patients underwent
carotid interventions

288 patients met study
inclusion criteria

171 CEA

117 CAS

Figure 1: Schematic of the patient population that was included in
the study data analysis. From June 2004 to December 2010 a total
of 303 patients received a carotid intervention at our institution. Of
these patients, 288 patients met study inclusion criteria. CEA was
performed in 171 patients, and CAS was performed in the remaining
117 patients.

received CAS, patients who received CEA were more likely
to have a history of diabetes (78.5% versus 56%; 𝑃 < 0.001),
obesity (93% versus 31%; 𝑃 < 0.001), COPD (47.7% versus
28.4%; 𝑃 < 0.001), atrial fibrillation (39% versus 16.4%; 𝑃 <
0.001), and hyperlipidemia (94.8% versus 81.9%; 𝑃 < 0.001).
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Major comorbidities among patients who received CAS
included hypertension (92.2%), hyperlipidemia (81.9%), and
CAD (74.1%; Table 1). Compared to patients who received
CEA, patients who received CAS were more likely to have
a history of smoking (56.9% versus 15.1%; 𝑃 < 0.001),
hypertension (92.2% versus 51.7%, 𝑃 < 0.001), CAD (74.1%
versus 31.4%; 𝑃 < 0.001), and PVD (40.5% versus 15.6%; 𝑃 <
0.001). Patients who received CAS also had a higher incidence
of carotid plaque calcification (27.6% versus 7%; 𝑃 < 0.001),
a history of transient ischemic attacks (TIAs; 39.7% versus
22.1%; 𝑃 = 0.002), and history of a prior CEA (33.6% versus
20.9%; 𝑃 = 0.02). There were no significant differences
observed in age groups, history of stroke, or contralateral
carotid artery stenosis between patients who received either
CAS or CEA. Postoperative neurological complications were
observed in 6 patients in each group, with no significant
difference observed between groups (5.1% for CAS versus
3.5% for CEA).
Ipsilateral microembolic lesions were detected on postoperative MRIs in a total of 56 patients (19.4%) over the study
period. Overall, the incidence of microembolic events was
higher among patients who underwent CAS compared to
CEA (36.8% versus 7.6%; 𝑃 < 0.001). Univariate analysis also
suggested that the incidence of perioperative microembolic
was affected by various patient variables, including diabetes
(𝑃 = 0.001), hypertension (𝑃 < 0.001), obesity (𝑃 < 0.001),
coronary artery disease (𝑃 < 0.001), COPD (𝑃 = 0.05), atrial
fibrillation (𝑃 = 0.005), smoking (𝑃 < 0.001), a history of
prior TIA (𝑃 = 0.005), and carotid lesion calcification (𝑃 =
0.008; Table 2). Incidence of microemboli was not affected
by history of contralateral carotid occlusion, prior CEA, or
prior stroke (Table 2). Multivariate logistic regression analysis
demonstrated that a patient history of hypertension (𝑃 =
0.03), smoking (𝑃 = 0.001), or a prior TIA (𝑃 = 0.04) was
most highly associated with the incidence of perioperative
microembolic events (Table 3).
Demographics of patients who developed perioperative
microemboli were then selectively evaluated. No patients
below the age of 55 years developed postoperative microemboli. Patients above the age of 60, stratified into incremental 10-year age groups, demonstrated unequal distributions
of incidence of perioperative microemboli (Table 4). The
majority of patients with perioperative microemboli were
between the ages 61 and 80; however the overall incidence
of microemboli across age groups was not significant and
was not influenced by type of carotid intervention that
they received. Univariate analysis of other patient variables
demonstrated that compared to patients who received CAS,
patients who received CEA and developed perioperative
microemboli were more likely to be obese (69.2% versus
34.9%; 𝑃 = 0.05; Table 4). On the other hand, patients who
received CAS and developed microemboli were more likely
to have a history of CAD (81.4% versus 46.2%; 𝑃 = 0.03).

5. Discussion
Microembolic events during carotid artery interventions
are well described, and are thought to occur with variable
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Table 2: Univariate analysis of incidence of microemboli in all
patients who received either CEA or CAS.
Patient demographic
Carotid intervention
CEA
CAS
Diabetes
Hypertension
Hyperlipidemia
Obesity
CAD
COPD
PVD
Atrial fibrillation
Smoking
History of CEA
Preop stroke
Preop TIA
Contralateral carotid
Occlusion
Plaque calcification

% of patients
with
microemboli

% of patients
with no
microemboli

7.6%
36.8%
51.8%
92.9%
92.9%
42.9%
73.2%
28.6%
35.7%
14.3%
67.9%
26.8%
25.0%
44.6%

70.2%
29.8%
80.2%
51.2%
89.5%
93.6%
30.2%
49.4%
13.4%
39.0%
10.5%
23.8%
18.0%
22.7%

0.001
<0.001
0.37
<0.001
<0.001
0.05
0.06
0.005
<0.001
0.89
0.53
0.005

7.1%

5.8%

0.88

26.8%

8.7%

0.008

𝑃 value
<0.001

CEA: carotid endarterectomy; CAS: carotid artery stenting; TIA: transient
ischemic attack.

Table 3: Multivariate analysis of incidence of microemboli in all
patients who received either CEA or CAS.
Variable
Carotid intervention
(CAS versus CEA)
Diabetes
Hypertension
Obesity
CAD
COPD
Atrial fibrillation
Smoking
Preop TIA
Plaque calcification

Multivariate regression analysis
𝑃 value

OR

95% CI

0.13

2.13

0.81–5.63

0.10
0.03
0.71
0.49
0.41
0.10
0.001
0.04
0.46

0.54
3.90
1.18
1.32
0.73
0.47
3.39
2.13
1.39

0.26–1.13
1.18–12.90
0.49–2.88
0.60–2.89
0.35–1.54
0.19–1.15
1.64–7.01
1.05–4.36
0.58–3.31

OR: odds ratio; CI: confidence interval.

incidence [1, 15, 16]. These events are not entirely benign,
since we and others have observed an association between
perioperative cerebral microembolization and short-term
memory decline [6–8]. Despite these characterizations, less
is known about the patient-related factors that may influence
the incidence of these microembolic events. We report an
analysis of the large series of patients from a single academic
institution who have undergone dedicated surveillance for
perioperative microemboli during carotid revascularization
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Table 4: Univariate analysis of demographics in patients who developed perioperative microemboli with either CEA or CAS.
Patient demographic
Age
<60
61–70
71–80
>80
Male
Smoking
Diabetes
Hypertension
Hyperlipidemia
Obesity (BMI > 30)
CAD
COPD
PVD
Atrial fibrillation
Prior CEA
Prior TIA
Prior Stroke
Contralateral carotid Occlusion
Plaque calcification
Plaque ulceration

Overall (𝑛 = 55)

CEA (𝑛 = 12)

CAS (𝑛 = 43)

10.7%
39.3%
30.3%
12.5%
96.4%
67.9%
51.8%
92.9%
92.9%
42.9%
73.2%
28.6%
35.7%
14.3%
26.8%
44.6%
25.0%
7.1%
26.8%
23.2%

8.3%
33.3%
33.3%
25.0%
92.3%
84.6%
69.2%
100%
100%
69.2%
46.2%
23.1%
38.5%
23.1%
7.7%
30.8%
15.4%
15.4%
15.4%
23.1%

11.6%
41.9%
30.2%
16.3%
97.7%
62.8%
46.5%
90.7%
90.7%
34.9%
81.4%
30.2%
34.9%
11.6%
32.6%
48.8%
27.9%
4.7%
30.2%
23.3%

here. This study is a contemporary update to two prior reports
that analyzed smaller patient subsets: one that evaluated a
cohort of 69 patients who received either CEA or CAS and
another that evaluated 67 patients who received CAS [13, 14].
In our current analysis we observed that patients who
received a carotid artery intervention and suffered microembolic events following revascularization were more likely to
have a history of hypertension, smoking, or a history of prior
TIAs. Of the patients who received CAS procedures, nearly
36.8% of them developed perioperative cerebral microemboli
events. Patients who received CAS and developed perioperative microemboli were also more likely to have CAD.
Far fewer patients developed microemboli with CEA (7.6%),
but those who did were more likely to be obese. These
findings further our understanding of specific patient-related
factors that may influence rates of perioperative cerebral
microemboli and aid in risk stratification of vulnerable
patient populations.
The reported incidence of perioperative microemboli
during carotid artery interventions has varied significantly
between recent reports, ranging from 17% to 70% [1, 17]. A
subgroup analysis of ICSS study patients who received preand postcarotid revascularization DWI evaluations demonstrated at least one new DWI lesion on posttreatment scans
of 50% of CAS patients and 17% of CEA patients, nearly a
3-fold increase in CAS patients [11]. In a recent systematic
review, microembolic events were reported to occur in 37%
of patients who underwent CAS and 10% of patients who
underwent CEA [18]. Early in our experience with CAS,
our institution reported a higher than expected incidence
of perioperative microemboli [1], which emphasized the

𝑃 value
0.99

0.41
0.19
0.21
0.56
0.56
0.05
0.03
0.74
0.99
0.37
0.15
0.34
0.48
0.23
0.48
0.99

need for continued surveillance and changes in our practice
paradigms [12]. More recently we have detailed rates of
microemboli that are dramatically lower [13], with the report
herein demonstrating an overall rate of microemboli at 36.8%
following carotid artery stenting procedures. We attribute
our steady decline in rates of perioperative microemboli
to guidelines that we implemented at the study institution,
which include the routine use of EPDs, utilization of closedcell stent systems (used in 67% of the total CAS patient population evaluated during in this study), early administration
of intraoperative heparin, elimination of arch angiograms if
adequate preoperative imaging is available, and the designation of specific practitioners for routine performance of CAS
[12, 13]. Similarly, others have observed decreased incidence
of microemboli with the use of closed-cell stents, eccentric
EPDs, and minimizing of supra-aortic endoluminal manipulation with catherizations and unnecessary angiograms [19,
20].
Rates of microemboli with CEA are consistently observed
to be lower than with CAS [1, 21, 22]. For example, Poppert
et al. found that 17% of patients who received CEA and
54% of patients who received CAS developed perioperative
microemboli, with smaller microembolic volumes among
patients who received CAS [23]. Operative technique is
thought to be the major factor influencing rates of perioperative microemboli with CEA. A systematic review of
32 reports, comprising 754 CEA operations, revealed that
selective shunting in high risk CEA patients was associated
with a significant reduction of perioperative microemboli
[18]. However, routine shunting with CEA has also been
shown to have acceptably low incidence rates of microemboli
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[24], which is in concordance with our cohort of CEA
patients. Interestingly, our study highlights obesity as an
independent risk factor for postoperative microemboli in
patients who receive CEA. We presume that this reflects the
technical challenges that are sometimes encountered with
surgical exposures of the carotid bifurcation in obese patients.
Carotid exposure in these situations may involve a more
aggressive manipulation of the diseased carotid bulb and
internal carotid artery, which can consequently increase the
risk of distal embolization.
Among patients who receive CAS, prior series have
demonstrated that symptomatic status or a history of TIAs
is important predictor of perioperative cerebral microembolization [13, 14, 25]. In effect, patients who have recent
symptoms (comprising nearly 30% of our overall study
population) are more likely to have recurrence of emboli,
particularly with catheterization and stenting. For this reason, carotid plaque stability, ulceration, echolucency, and/or
calcification are also hypothesized to impact the risk of
CAS-associated microembolization [26–28]. However, some
series have not found any significant associations between
carotid plaque characteristics and the incidence of microembolization [16, 29]. Additionally, difficult aortic arch anatomy
and calcification have been implicated with higher risks
of perioperative cerebral microembolization [16, 30]. A
recent retrospective review of 837 patients found that in
addition to age, carotid lesion length and eccentricity, type
III aortic arches were significantly associated with ischemic
cerebral lesions following CAS [31]. Similarly, in our study,
carotid plaque calcification was an observed risk factor
for perioperative microembolization on univariate analysis.
However, on multivariate analysis, this did not emerge as
independent risk factor, suggesting that although carotid
plaque anatomy/morphology is certainly a good measure
of plaque stability, in a large percentage of patients, CAS
can be performed without a significantly higher risk of
microembolization.
In our study population, the majority of patients with
CAD (74%) received CAS (Table 1). Our preference of offering CAS to patients with severe CAD, which is evident by
significantly impaired cardiac function or reversibility on
preoperative cardiac perfusion scanning, is also reflected in
the findings of the carotid revascularization endarterectomy
versus stenting trial (CREST) [32]. In this trial, a higher
incidence of myocardial infarction and elevation in cardiac
biomarkers was observed in patients who received CEA.
Interestingly, our study observed that CAD is an independent
predictor of perioperative microembolization in patients who
receive CAS, as opposed to other markers of vascular disease
severity such as PVD, a history of prior stroke, or contralateral
carotid occlusion. In fact, in our cohort of patients, 81% of
those who had CAS and developed perioperative microemboli were also found to have CAD (Table 4). We speculate that
such patients, with impaired cardiac function, are more susceptible to develop intraoperative hemodynamic instability.
Whether this could influence rates of perioperative microemboli is certainly a topic that warrants further investigation.
Furthermore, hypertension and smoking are among the
leading modern day contributors of major disease and
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account for increased morbidity, mortality, and potential
life-years lost [33]. Not surprisingly, both of these factors
were found to significantly affect the incidence of cerebral
microemboli with any carotid artery intervention (either
CEA or CAS). Thus, proactive patient consultation for
smoking cessation and optimal blood pressure management
should be advocated prior to any type of carotid revascularization procedure, particularly in patients with asymptomatic
nonrapidly progressing carotid artery stenosis. In symptomatic patients, and patients with other comorbidities such
as obesity and/or CAD, appropriate patient consultations
and in-depth discussions about the risks of perioperative
cerebral microembolization (independent of stroke) should
be provided prior to attempts of carotid revascularization.
In this large cohort of patients, age was not observed
to be a risk factor for the incidence of microemboli. In a
prior report we similarly observed no significant associations between patient age and the incidence of ipsilateral
microemboli, although patients above the age of 76 were
found to have a slightly higher incidence of contralateral
microemboli with CAS [13]. Accordingly, in a smaller cohort
of patients, Kastrup et al. found an increased incidence of
perioperative microemboli in octogenarians; however they
argued that this finding most likely stemmed from the fact
that the majority of octogenarians in the study were patients
with significant aortic arch calcification that increased the
risk of intraoperative microembolization [26]. Nevertheless,
the lack of significant association between age and the risk of
perioperative microembolization diverges from compelling
evidence demonstrating increased periprocedural stroke
rates in older patients following CAS. Most notably, results
from the lead-in phase of the CREST trial demonstrated
a 12% stroke and death rate among octogenarians, which
resulted in exclusion of octogenarians from the remainder
of the trial [34]. Upon completion of the trial, an interaction
between patient age and carotid procedural treatment efficacy
was once again confirmed, with better procedural efficacy
in patients below the age of 70, and better outcomes in
patients below the age of 64 [35]. It is unclear why patient
age may influence periprocedural stroke rates, but not as
profoundly impact periprocedural microembolization rates.
Perhaps these findings argue that subclinical microemboli
and more clinically evident perioperative strokes are not on
the same continuum and may be differentially influenced by
patient demographics and comorbidities.
The clinical sequela of perioperative microemboli has
been a subject of debate in recent years. Some have suggested that microemboli are transient and are clinically less
relevant given the fact that the majority of acute microembolic events are only detectable on DWI in the first 48–72
hours following the embolic event [36, 37]. Microembolic
lesions larger than 60 mm2 do demonstrate residual MRI
abnormalities [37]. Studies have shown that CAS patients
with new lesions on postoperative DWI were more likely
to have a postoperative score decline on the Mini Mental
Status Exam, and an increase in venous serum biomarkers
associated with neurologic ischemia and brain injury, such as
neuron-specific enolase and calcium-binding protein S100B
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[38]. Similarly, we recently demonstrated that patients who
developed postoperative microembolic lesions were more
likely to have a decline in memory using the Rey Auditory
Verbal Learning Test [8].
A major limitation of this study is the chart reviewbased extraction of patient specific data, which may be
subject to measurement bias. Given the time span of the
study, over the course of 6 years, a mild cohort effect may
be inadvertently introduced since practice paradigms and
technology preferences have continued to evolve over time,
particularly among patients who received CAS. These biases
are minimized since for the most part the same practitioners
performed the majority of the carotid interventions reported
in the study. Our current study did not include the theoretical contributions of aortic arch anatomy to the incidence
perioperative cerebral microemboli during CAS; however
we anticipate that this would have minimal contribution in
patients less than 80 years old [26]. Finally, although we
carefully evaluated the presence and absence of microemboli,
the size and location of each lesion was not delineated. In
the future, we anticipate incorporating volumetric analysis
in postoperative assessments of all patient DWI scans as
a more accurate method to characterize the perioperative
microembolic burden.

6. Conclusion
In conclusion, we demonstrate here that specific patient populations are more prone to perioperative microemboli following carotid intervention. Although CAS patients develop
higher rates of microemboli, a nonnegligible number of
CEA patients can also develop perioperative microemboli.
With continued risk stratification of patients undergoing
carotid interventions, we anticipate a continued decline in
perioperative cerebral microemboli.
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